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E-mail address: znagy@utep.edu (Z.S. Nagy).In the current work, we report that speciﬁc inhibition of Janus tyrosine kinase (JAK3) via NC1153
induces apoptosis of certain leukemia/lymphoma cell lines. Affymetrix microarray proﬁling follow-
ing NC1153 treatment unveiled JAK3 dependent survival modulating pathways (p53, TGF-b, TNFR
and ER stress) in Kit225 cells. IL-2 responsive NC1153 target genes were regulated in human JAK3
positive, but not in JAK3 negative lymphoid tumor cells. Moreover, primary lymphoma samples
revealed that a number of these genes were reciprocally regulated during disease progression and
JAK3 inhibition suggesting that downstream targets of JAK3 could be exploited in the development
of novel cancer treatment regimes.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Janus tyrosine kinases (JAK1, 2, 3 and TYK2) mediate cellular
processes induced by select cytokines, growth factors and interleu-
kins [1]. While JAK1, 2 and TYK2 are ubiquitously expressed, JAK3
is found primarily in activated lymphocytes, monocytes and natu-
ral killer (NK) cells [2]. Genetic abnormalities that disrupt JAK3 are
manifested as severe combined immunodeﬁciency syndrome
(SCID) in humans [3]. Since these patients fail to exhibit pathology
outside the immune system, JAK3 represents an attractive target
for the development of novel therapeutics for controlling autoim-
mune disease and organ transplant rejection [4].chemical Societies. Published by E
ma; B2M, b-2-microglobulin;
glyceraldehyde 3-phosphate
ly-(ADP-ribose) polymerase;
tivator of transcription; TGF,
r; qRT2 PCR, quantitativereal
; WB, Western blot
as at El Paso, Department of
Paso, TX 79968, USA. Fax: +1Recently, aberrant regulation of JAK kinases have been associ-
ated with malignant transformation [5] and nominated as thera-
peutic targets in the treatment of cancer [6]. Overactive JAK3 has
been reported in mantle cell lymphoma [7], HTLV-1 induced adult
T-cell lymphoma/leukemia [4,8], cutaneous T-cell lymphoma [9]
and anaplastic large-cell lymphoma (ALCL) [10].
We have previously reported that the Mannich base NC1153
preferentially inhibited JAK3 compared with JAK2 and several
other kinases in in vitro assays [11]. The present study sought to
identify the effect of NC1153-mediated JAK3 blockade on lymphoid
cancer cell viability and dissect the molecular mechanism by
which JAK3 promotes lymphoid cell survival.
2. Materials and methods
2.1. Cell culture and treatment
The human cell lines YT (lymphoma) [12], Molt-3 (thymus-de-
rived T-lymphocyte) [13], H9 (CD4+ T-cell derived), [14] and
Kit225 (IL-2 dependent leukemia) [15] were cultured as described
[16]. IL-2 was obtained from NCI Preclinical Repository. Gamma-
irradiation was performed with a Precision 160 irradiator (4000
Rad). Cells were treated with NC1153 (25 lM) or DMSO (0.1%)
for 12 h unless otherwise noted.lsevier B.V. All rights reserved.
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Cell viability was assessed as described in [17].2.3. RNA isolation, cDNA synthesis and RT PCR
Total RNA was isolated using the RNeasy kit (Qiagen). cDNA was
synthesized with BioRad’s iScript cDNA Synthesis Kit. JAK3 prim-
ers: forward caagtacatctcacagctgggcaag, reverse ctaggccgaagtcagc-
gatcttg.2.4. Microarray analysis
Microarray analysis were carried out at the Microarray Core
Facility, Baylor College of Medicine, Houston, TX (www.bcm.edu/
mcfweb) and the data is available at the Gene Expression OmnibusFig. 1. (A) NC1153 inhibits cell viability of Kit225 cells in a dose dependent manner. Kit22
cell viability was determined by MTS assays at 48 and 72 h. (B) NC1153 induces the cleav
cells were treated as above for 15 h and Western blotted with the antibodies indicate
independent experiments).Database (https://www.ncbi.nlm.nih.gov/projects/geo/ Accession:
GSE17007).
2.5. Gene ontology analysis
Gene ontology (GO) categories were identiﬁed with the Cyto-
scape2.5/BiNGO software [18].
2.6. Cell lysis and Western blotting
Antibodies to phosphotyrosine (PY)-signal transducer and acti-
vator of transcription (STAT5), STAT5 and glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) were used as previously described
[17]. Antibodies were obtained from: BD Biosciences: STAT5,
ERK; Millipore: PY-STAT5; Sigma: a-tubulin; Research Diagnostics,
Inc.: GAPDH; Cell Signaling Technology: phospho-ERK, poly-(ADP-
ribose) polymerase (PARP); Imgenex: TP53INP1, Abcam: DDIT3;5 or Molt-3 cells were treated with medium (NT), DMSO or NC1153 as indicated and
age of the apoptosis marker PARP1 in Kit225 but not Molt-3 cells. Kit225 and Molt-3
d to the right. Molecular weight markers (kDa) are shown to the left (from two
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tion recommended by the manufacturer.
2.7. Separation of cytosolic and nuclear proteins
Nuclear and cytoplasmic proteins were isolated with Nuclear
Extraction Kit from Panomics, Inc.
2.8. RT2 proﬁler PCR arrays
Human PCR Arrays, individually available primer mixes for the
validation of the array results and 2 SYBR Green Mastermix were
purchased from SA Biosciences. Q RT2 PCR was performed using a
BioRad iQ5 thermocycler. Treatments were performed in triplicates
and data was analyzed using the DDCt method.
2.9. TissueScan lymphoma panel and statistical analysis
TissueScan Lymphoma Tissue qPCR Arrays containing nor-
malized amounts of cDNA (to b-actin) were purchased from
OriGene and measurements analyzed with the DCt method.
For each variable Analysis of Variance (ANOVA) with the F-test
P-value was used to compare transcript expression level across
the disease stages. Statistical signiﬁcance (P-value <0.05 was
determined by the least signiﬁcant difference (LSD) post-hoc
procedure.
2.10. Statistical analyses
Student’s t-tests were employed for pair-wise comparison of
treatments, using SigmaStat3.1 (SyStat, Aspire Software Interna-Fig. 2. (A) NC1153 disrupts JAK3 tyrosine phosphorylation. Kit225 cells depleted of IL-
stimulated with IL-2 for 10 min, and immuno-precipitated for JAK3. Western blot w
phosphorylation. Kit225 cells were treated with NC1153 (N) or DMSO (D) for 12 h, and
(three independent experiments). (C) JAK3 protein expression in multiple human leukem
and Western blotted for JAK3. (D) JAK3 mRNA expression in multiple human leukemia ce
subjected to RT PCR analysis with primers speciﬁc to JAK3. NTC: no template control.tional) software. P-values <0.05 were considered statistically
signiﬁcant.3. Results and discussion
3.1. NC1153 diminishes the viability of Kit225 leukemia cells in a dose
dependent manner
The search for selective JAK3 inhibitors is ongoing [19,20]. We
have previously showed that the Mannich base NC1153 signiﬁ-
cantly prolonged heart allograft survival [11] by inhibiting T-cell
function via uncoupling JAK3. STAT5, a downstream target mole-
cule of JAK3, plays a critical role in maintaining lymphoid cell sur-
vival [21,22]. Therefore, we sought to test the effect of NC1153 on
the viability of lymphoid tumor cell lines. In Fig. 1A, IL-2 dependent
Kit225 cells growing in the presence of IL-2 and non-IL-2 depen-
dent Molt-3 leukemia cells were treated with ascending concentra-
tions of NC1153. Viability of Kit225 cells showed 55% inhibition by
48 h at 7.5 lM, while the same dose had no effect on Molt-3 cells.
Furthermore, while 7.5 lMNC1153 reduced Kit225 cell viability by
75% at 72 h, it resulted only 15% reduction in Molt-3 cells. YT lym-
phoma cells and activated human PBMCs were also sensitive to
this compound, but other cells (Molt-3, H9, SupT1) were refractory
(data not shown). Higher concentrations of NC1153 (ﬁve-times the
established IC50 (2.5 lM) [11]) did reduce cell viability of Molt-3
cells which could be due to off-target effects. However, our exten-
sive in vitro proﬁling of receptor, non-receptor tyrosine kinases
and kinases that mediate cell cycle or proliferation (Supplementary
Fig. 1) does not support this explanation.2 for 45 h were treated with NC1153 (N) or DMSO (D) for an additional 3 h then
as carried out for PY, and then for JAK3. (B) NC1153 inhibits STAT5 tyrosine
Western blotted for PY-STAT5 followed by a re-blot for STAT5 and then a-tubulin
ia cells. Kit225 (K), H9 (H), Molt-3 (M) and YT (Y) cells were immuno-precipitated
lls. Total RNA was isolated from Kit225 (K), YT (Y), H9 (H) and Molt-3 (M) cells and
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To determine the mechanism of NC1153 induced reduction of
cell viability, Western blot (WB) analysis was performed for the
cleavage of the apoptotic marker PARP1. As shown in Fig. 1B,
NC1153 reduced STAT5 tyrosine phosphorylation in Kit225 cells
in a dose dependent manner that correlated with a dramatic
increase in Caspase-3 activation as detected by the cleavage of
full length PARP1, a marker of cells undergoing apoptotic death
[23]. On the other hand, while minimal loss of STAT5 tyrosine
phosphorylation occurred at the highest NC1153 concentrations
tested in Molt-3 cells, no PARP1 cleavage resulted. The integrity
of caspase-3 mediated PARP1 cleavage in Molt-3 cells was veri-Fig. 3. Validation of NC1153 target genes in JAK3 positive and JAK3 negative human lymp
DMSO (D) or NC1153 (N) was subjected to qRT2 PCR with primers as indicated above th
(B2M). Data is representative of two independent experiments. P < 0.001.ﬁed by UV exposure (data not shown). These data suggest that
JAK3 blockade differentially affects lymphoid cells.
3.3. NC1153 uncouples the activation of the cell survival-mediating
JAK3/STAT5 pathway
Next, Kit225 cells treated with NC1153 or DMSO were analyzed
for the activation of JAK3 (Fig. 2A) and STAT5 (Fig. 2B) by WBs.
Both JAK3 and STAT5 tyrosine phosphorylation was signiﬁcantly
reduced or abolished, respectively. YT, Molt-3 and H9 cells were
also analyzed for the activation of JAK3. While YT cells showed
similar response to Kit225 cells (data not shown), several attempts
failed to detect JAK3 protein in Molt-3 and H9 cells (Fig. 2C). RThoid cell lines. Total RNA obtained from H9, Molt-3, Kit225 and YT cells treated with
e graphs. Relative gene expression changes were normalized to b-2-microglobulin
ig. 4. NC1153 induces the expression of DDIT3 and TP53INP1 proteins. Kit225 or
olt-3 cells were treated with NC1153 or DMSO, or subjected to gamma-irradiation
s indicated. Total cell lysates at 9 h (upper panel) or nuclear extracts at 24 h (lower
anel) were then prepared andWestern blotted for DDIT3 (upper panel, normalized
GAPDH) or TP53INP1 (lower panel, normalized to Lamin A/C).
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able in H9 cells and expressed at low levels in Molt-3 cells.
Whether the low mRNA abundance is sufﬁcient to yield protein
expression is not clear, but it is possible that decreased Molt-3 cell
viability with higher concentrations of NC1153 may be due to tar-
geting low levels of JAK3. It should be noted that in order to iden-
tify the enzymatically active form of JAK3 for both protein and
mRNA the catalytic domain was detected. Whether any truncated
or fusion version of JAK3 might exist in Molt-3 and H9 cells re-
mains to be determined.
3.4. JAK3 blockade regulates a novel pool of apoptosis mediating genes
Next, mRNA expression proﬁle of NC1153 treated Kit225 cells
was established using Affymetrix Human Genome U133 Plus 2.0
microarrays. These experiments revealed 197 down- and 238 up-
regulated annotated genes with greater than twofold changes
(two independent experiments, P < 0.05). In order to obtain global
insight into the mechanism of action for NC1153, gene ontology
analysis was performed using Cytoscape/BiNGO software. Thirty
six genes responsible for cellular death were signiﬁcantly overrep-
resented (corrected P-value 6.61  104); of which twenty one
genes were validated by quantitative real time reverse transcrip-
tase polymerase chain reaction (qRT2 PCR) arrays (Supplementary
Table 1). According to the current dogma, JAK3 is the primary exec-
utor of c-cytokine (such as IL-2) driven signals [24] and conse-
quently, NC1153 target genes should respond to IL-2. Indeed, 11
NC1153 target genes responded to IL-2 in a reciprocal manner to
NC1153 (Supplementary Table 1 and Supplementary Fig. 2). As tu-
mor necrosis factor TNFRSF8/CD30 is the marker for patients with
Hodgkin and systemic ALC lymphoma, it was also validated. Genes
that promote apoptosis such as mediators of the p53 pathway
(JMY, TP53INP1), executors of apoptosis upon ER stress (DDIT3)
or cytokine withdrawal (FOXO3A, TSC22D3) (Supplementary
Fig. 2) were up-regulated by NC1153 and down-regulated by IL-
2. Conversely, genes that promote growth such as TBRG4 and
TNFSF14/LIGHT were down-regulated by NC1153 and up-regu-
lated by IL-2. It should be noted that none of the newly identiﬁed
genes responded to IL-2 in a parallel manner to NC1153; rather,
their response was below the twofold threshold (data not shown).
3.5. Select IL-2 responsive NC1153 target genes are differentially
expressed in JAK3 positive, versus JAK3 negative, leukemia cells
In order to expand the NC1153 gene proﬁle studies, the putative
NC1153 target gene levels were examined in multiple human leu-
kemia cells by qRT2 PCR analysis. TNFSF14/LIGHT and TSC22D3
were only expressed in Kit225 cells. The remaining nine genes
could be separated into three groups based on their response to
NC1153. The ﬁrst group contained the JAK3-restricted responders:
FOXO3A and transforming growth factorB1 expression was up- and
down-regulated only in Kit225 and YT cells, respectively, and dis-
played no changes in the other cells (data not shown). TNFSF8/
CD30 was down-regulated in YT and Kit225 cells but not in H9
and Molt-3 cells. Similarly, JMY, TP53INP1 and PDCD4 were up-
regulated by NC1153 in Kit225 and YT cells but not in the others
(Fig. 3). The second group contained the universal responders:
TBRG4 and DDIT3, with their levels down- and up-regulated,
respectively, in all cell lines by NC1153 (Fig. 3). BCL6, the only
member of the third group was up-regulated in Kit225, H9 and
Molt-3 cells only but showed no change in YT cells (Supplementary
Fig. 3). Taken together, the majority (8 of 11) of the putative target
genes responded to NC1153 only in JAK3 positive cells. Next, the
apoptosis regulator proteins DDIT3 and TP53INP1 were measured
by Western blotting in Kit225 or Molt-3 cells (Fig. 4). JAK3 inhibi-
tion caused elevated TP53INP1 (lower panel) exclusively in Kit225F
M
a
p
tocells (gamma irradiated cells were used as a positive control),
while the ER stress regulator DDIT3 (upper panel) was induced in
both cell lines. This latter phenomenon could be due to the inhibi-
tion of either JAK3 that is below the sensitivity of Western blotting
or another yet unidentiﬁed molecule ubiquitously present in these
cells. The ﬁrst hypothesis is supported by the JAK3 RT PCR experi-
ment (Fig. 2D) which showed minimal but still detectable amounts
of JAK3 mRNA in Molt-3 cells.
3.6. Select NC1153 target genes are reciprocally regulated by JAK3
inhibition and disease progression in certain human lymphomas
To translate our ﬁndings from tumor cell lines to primary tumor
samples we measured the transcript levels of the NC1153 target
genes in a panel of various human lymphomas isolated at different
stages of the diseases as compared to non-cancerous samples (Sup-
plementary Table 2). Statistical analyses demonstrated that several
NC1153 target genes signiﬁcantly changed during the transition
from normal to disease stages (P < 0.05, Table 1). The pro-prolifer-
ation molecule TNFSF14/LIGHT was up-regulated in peripheral T-
cell lymphomas and reduced by JAK3 inhibition. TBRG4 was up-
regulated in mantle cell lymphomas and decreased by NC1153.
The function of TBRG4 in mammalian cells remains unclear, but
it was shown to be a positive modulator of cell cycle in yeast
[25]. The pro-apoptotic PDCD4 (up-regulated by NC1153) was
down-regulated in Hodgkin, ALC, follicular and peripheral T-cell
lymphomas. Whether JAK3 plays a role in follicular and peripheral
T-cell lymphomas has yet to be explored in detail. However, IL-9
activated JAK3 [26] as well as IL-21 activated STAT5 [27] were
associated with Hodgkin lymphomagenesis. IL-9 was also shown
to potentiate the activity of ALK kinase in ALCL via JAK3 [10]. Taken
together, it would be important to examine whether the down-reg-
ulation of PDCD4 is due to JAK3 activity in these disorders. The pro-
apoptotic FOXO3A was also down-regulated in Hodgkin, follicular
and diffuse large B-cell lymphomas while JAK3 inhibition induced
its the expression. Whether loss of FOXO3A in these lymphomas is
due to increased JAK3 activity or is the result of gene deletion [28]
remains to be determined. Taken together, four putative NC1153
target genes were reciprocally regulated by disease progression
in select lymphomas suggesting increased JAK3 activity might con-
tribute to their malignant phenotype.
In the present study we report that JAK3 inhibition may be use-
ful for blocking uncontrolled growth of certain subsets of cancer-
ous lymphocytes that depend on hyperactive JAK3/STAT5. These
Table 1
NC1153 target gene expression in human lymphoma patient samples. Statistical analysis of NC1153 target transcript levels in human lymphoma samples as compared to non-
disease controls across disease stages. Means followed by the same letter are not signiﬁcantly different at the 0.05 level. Characters in bold indicate genes reciprocally regulated
by NC1153 and disease progression.
Transcript N Stage I Stage IE Stage II Stage IIE Stage IV F-test P-
value
Effect of disease
progression
Effect of
NC1153
Lymphoma, Hodgkin TGFB1 1.4726b 1.0922a 1.8473b 0.0354 down/up down
FOXO3A 0.0670b 0.0220a 0.0253ab 0.0328 down up
PDCD4 0.1559b 0.0638a 0.0614a 0.0045 down up
Lymphoma, anaplastic
large cell
PDCD4 0.1559b 0.0211a 0.0022 down up
Lymphoma, follicular BCL6 0.1557a 0.4184b 0.4020b 0.4748b 0.3943b 0.0012 up up
TGFB1 1.4726b 0.6407a 0.8922ab 0.9046ab 0.5904a 0.0021 down down
FOXO3A 0.0670b 0.0163a 0.0178ab 0.0144ab 0.0142a 0.0211 down up
PDCD4 0.1559b 0.0520a 0.0489a 0.0466a 0.0361a <0.0001 down up
Lymphoma, large B-cell,
diffuse
LIGHT 0.0422b 0.0154a 0.0250ab 0.0004a 0.0074ab 0.0402 down down
FOXO3A 0.0670b 0.0136a 0.0486ab 0.0140ab 0.0211ab 0.0232 down up
DDIT3 0.0811a 0.0583a 0.1650bc 0.223c 0.0531ab 0.0300 up up
Lymphoma, mantle cell TP53INP1 0.2489a 0.0869a 0.8324b 0.0292 up up
TBRG4 0.1561a 0.1545a 0.3266b 0.0349 up down
PDCD4 0.1559a 0.1787a 0.5607b <0.0001 up up
Lymphoma, peripheral T-
cell
LIGHT 0.0422a 0.1407b 0.0249 up down
PDCD4 0.1559b 0.0344a 0.0127a 0.0006 down up
DDIT3 0.0811ab 0.0343a 0.1523b 0.0494 down/up up
1520 Z.S. Nagy et al. / FEBS Letters 584 (2010) 1515–1520abnormally expressed genes could be perhaps exploited as targets
for novel therapies or as biomarkers.
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